An in vivo study by Liu et al. uncovered that PD-1 or CTLA-4 monotherapy or combinatorial therapy reduced suppressive potential of PD-1+CTLA-4+ MDSCs, and reduced tumor growth and improved survival [100]. This evidence concerns the gene PDCD1 and neoplasm.